Histogenics Corporation to Present at Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. INFY
3. ISRG
4. JWN
5. BZUN

6. ELV
7. PPG
8. TSM
9. SNV
10. AXP

Get Alerts HSGX Hot Sheet

Price: $0.16 --0%

Overall Analyst Rating:
BUY (= Flat)

Join SI Premium – FREE

WALTHAM, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.

H.C. Wainwright Global Life Sciences Conference – Monte Carlo, Monaco (April 8-10, 2018)Jonathan Lieber, Histogenics’ CFO, will present a corporate overview on Tuesday, April 10, 2018 at 11:55a.m. CEST / 5:55 a.m. EDT.

Alliance for Regenerative Medicine 6th Annual Cell and Gene Investor Day – New York, NY (April 17, 2018)Sponsored by the Alliance for Regenerative Medicine, the conference provides institutional, strategic and venture investors a unique opportunity to gain insight into over 30 leading cell and gene therapy companies. Mr. Lieber will present a corporate overview on Tuesday, April 17, 2018 at 9:10 a.m. EDT.

To access live audio webcasts of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.

About Histogenics Corporation

Histogenics (Nasdaq: HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.

Contact:

Investor Relations Tel: +1 (781) 547-7909[email protected]